| Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia |
|
Blood Cancer Journal |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Drug development in higher-risk myelodysplastic syndromes |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT |
|
Blood Neoplasia |
Myelodysplastic Syndromes (MDS) |
| Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS |
|
Blood Neoplasia |
Myelodysplastic Syndromes (MDS) |
| CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? |
|
Blood Neoplasia |
Myelodysplastic Syndromes (MDS) |
| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
